Top Analyst Upgrades and Downgrades: AMD, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate, Sonos, Starbucks, T-Mobile and More

Stocks had seen some profit taking on Tuesday, but the indexes were all marginally higher on Wednesday. This week is the thickest patch of earnings and on Wednesday is also the Federal Open Market Committee announcement and the day of technology company hearings in Washington, D.C. Stocks have recaptured most of their losses from the plunge-depth selling lows of March, and earnings seasons is still bringing a very mixed reaction for the main market leadership stocks. And with an election coming up, and what is still a very deep recession, investors need to be considering how they want their assets positioned for the second half of 2020 and as 2021 comes into focus.

24/7 Wall St. reviews dozens of analyst research reports each day of the week in an effort to find new ideas for long-term investors and short-term traders alike. Some analyst reports cover stocks to buy, and others cover stocks to sell or avoid.

Remember that no single analyst report should be used as a sole basis for any buying or selling decision. Consensus analyst target prices are from Refinitiv.

These are the top analyst calls we have seen on Wednesday, July 29, 2020.

Advanced Micro Devices Inc. (NASDAQ: AMD) was down almost 2% at $67.61 ahead of earnings but was last seen up 11% at $75.40 on Wednesday morning. Wedbush Securities reiterated its Outperform rating and raised its target to $85 from $75, and Susquehanna raised AMD to Positive from Neutral. Morgan Stanley maintained its Equal Weight rating but raised its target to $73 from $56.

Amgen Inc. (NASDAQ: AMGN) was maintained as Overweight but its price target was cut to $281 from $285 at Morgan Stanley. Holdings Inc. (NYSE: BILL) was started as Outperform with a $103 target price (versus an $85.10 prior close) at Oppenheimer.

Brookfield Infrastructure Partners L.P. (NYSE: BIP) was downgraded to Underperform from Neutral at Credit Suisse

DexCom Inc. (NASDAQ: DXCM) was reiterated as Outperform and its target price was raised to $485 from $465 at SVB Leerink, and Morgan Stanley reiterated its Equal Weight rating but raised its target to $428 from $377. Shares were last seen up almost 2% at $426.00 after earnings.

eBay Inc. (NASDAQ: EBAY) was down 1.5% at $56.35 ahead of earnings and was last seen down 2.5% at $54.95 on post-earnings profit-taking. Barclays reiterated eBay as Overweight and raised its price target to $82 from $77. Morgan Stanley reiterated its Equal Weight rating but raised its target from $62 to $64.

FireEye Inc. (NASDAQ: FEYE) was up 1.1% at $13.38 ahead of earnings but was last seen trading up over 13% at $15.20 on Wednesday’s post-earnings reaction. Barclays reiterated it as Equal Weight but raised its price target to $17 from $12. Wedbush maintained its Neutral rating but raised its target to $15 from $12. The consensus target price was $13.87.

Flexion Therapeutics Inc. (NASDAQ: FLXN) was started as Outperform with a $19 target price (versus a $12.49 close) at Credit Suisse.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.